Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TYMP | P19971 | 4/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | GAPDH | P04406 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481856 | 0.97 | KDM4E (0.39) | KDM4ETYMPPRMT6GAPDHTAS1R3 | |
| SCHEMBL29881809 | 0.97 | KDM4E (0.39) | KDM4ETYMPPRMT6GAPDHTAS1R3 | |
| SCHEMBL27216196 | 0.93 | KDM4E (0.38) | KDM4ETYMPPRMT6GAPDH | |
| SCHEMBL22301423 | 0.93 | TYMP (0.38) | KDM4ETYMPPRMT6GAPDH | |
| SCHEMBL20474396 | 0.91 | TYMP (0.39) | KDM4ETYMPPRMT6GAPDHTAS1R3 | |
| SCHEMBL18490321 | 0.91 | TYMP (0.39) | KDM4ETYMPPRMT6GAPDHTAS1R3 | |
| SCHEMBL22301428 | 0.91 | TYMP (0.37) | KDM4ETYMPPRMT6GAPDHTAS1R3 | |
| SCHEMBL18490433 | 0.91 | KDM4E (0.38) | KDM4ETYMPPRMT6GAPDHTAS1R3 | |
| SCHEMBL22301453 | 0.90 | TYMP (0.37) | KDM4ETYMPPRMT6GAPDHTAS1R3 | |
| SCHEMBL22301452 | 0.89 | TYMP (0.39) | KDM4ETYMPPRMT6GAPDHTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TYMP 1508/4885PRMT6 3865/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TYMP 1508/4885PRMT6 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.